A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC).
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Non-Small Cell Lung Cancer|Hepatocellular Carcinoma
DRUG: Ramucirumab|DRUG: MEDI4736
Number of Participants with Dose Limiting Toxicities (DLTs), Cycle 1 (up to 28 days)
Percentage of Participants with a Best Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR), Baseline to Disease Progression (Approximately 22 Months)|Proportion of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR), Baseline to Disease Progression (Approximately 22 Months)|Duration of Response (DoR), Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Approximately 22 Months)|Time to First Response (TTR), Baseline to Date of CR or PR (Approximately 22 Months)|Progression Free Survival (PFS), Baseline to Progressive Disease or Death from Any Cause (Approximately 22 Months)|Overall Survival (OS), Baseline to Progressive Disease or Death from Any Cause (Approximately 32 Months)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab and MEDI4736, Predose Cycle 1 Day 1 through Follow Up (Approximately 22 Months)|PK: Minimum Concentration (Cmin) of Ramucirumab and MEDI4736, Predose Cycle 1 Day 1 through Follow up (Approximately 22 Months)|Number of Participants with Treatment Emergent Anti Ramucirumab Antibodies, Predose Cycle 1 Day 1 through Follow Up (Approximately 22 Months)|Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies, Predose Cycle 1 Day 1 through Follow Up (Approximately 22 Months)
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC).